What were Telix Pharmaceuticals' (NASDAQ:TLX) Q1 2026 revenue results?

Telix Pharmaceuticals reported Q1 2026 group revenue of $230 million, marking a 24% increase year-over-year and an 11% sequential rise from the previous quarter.

What drove Telix's strong Q1 2026 performance?

The strong performance was primarily driven by the commercial success of Telix’s precision medicine portfolio, with particular emphasis on its flagship imaging agents.

What are Telix's R&D expenditure projections for 2026?

The company has guided for research and development (R&D) expenditures between $200 million and $240 million for the full year 2026.

What clinical milestone did Telix achieve in Q1 2026?

Telix reached a significant milestone with the first part of its ProstACT study meeting all primary safety and dosimetry goals, supporting the development of its prostate cancer therapeutic candidates.

Image for illustrative purposes only. Not a real photo.

Telix Pharmaceuticals posts 24% revenue growth in first quarter of 2026

Written by Jon CuthbertPublished Apr 7, 2026, 12:00 AM

Telix Pharmaceuticals (NASDAQ:TLX), a global leader in radiopharmaceutical precision medicine, has reported Q1 2026 group revenue of $230 million, representing a 24% increase over the same period last year and an 11% sequential rise from the previous quarter.

The strong quarterly performance was primarily driven by the continued commercial success of the company’s precision medicine portfolio, anchored by its flagship imaging agents.

Following the results, Telix reaffirmed its full-year 2026 revenue guidance of $950 million to $970 million, alongside research and development (R&D) expenditure guidance of $200 million to $240 million.

On the clinical front, Telix reached a significant milestone as the first part of its ProstACT study met all primary safety and dosimetry goals.

This progress supports the ongoing development of the company’s therapeutic candidates for prostate cancer.

Additionally, the firm advanced several regulatory milestones, including New Drug Application (NDA) and Marketing Authorisation Application (MAA) submissions across the United States, Europe, and China.

The company's focus remains on scaling its vertically integrated supply chain to meet the rising global demand for radiopharmaceuticals.

In the U.S. market, Telix has benefited from the expanded adoption of PSMA-PET imaging, where its products have established a leading position in the diagnostic space.